Patents Examined by Jeanine Goldberg
  • Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease
    Patent number: 7790370
    Abstract: The present invention provides a method of diagnosing or predicting susceptibility to a clinical subtype of Crohn's disease characterized by fibrostenosing disease by determining the presence or absence in an individual of a fibrostenosis-predisposing allele linked to a NOD2/CARD15 locus, where the presence of the fibrostenosis-predisposing allele is diagnostic of or predictive of susceptibility to the clinical subtype of Crohn's disease characterized by fibrostenosing disease. In a method of the invention, the clinical subtype of Crohn's disease can be, for example, characterized by fibrostenosing disease independent of small bowel involvement.
    Type: Grant
    Filed: July 30, 2003
    Date of Patent: September 7, 2010
    Assignee: Cedars-Sinai Medical Center
    Inventors: Maria T. Abreu, Kent D. Taylor, Jerome I. Rotter, Huiying Yang, Stephan R. Targan
  • Methods for predicting late onset Alzheimer disease in an individual
    Patent number: 7771937
    Abstract: Methods for diagnosis or prognosis of late onset Alzheimer disease in an individual are provided which comprise detecting at least one polymorphism of a low-density lipoprotein receptor related protein 6 gene.
    Type: Grant
    Filed: May 20, 2005
    Date of Patent: August 10, 2010
    Assignee: University of Washington
    Inventors: Randall Todd Moon, Giancarlo De Ferrari
  • Feline hemoplasma isolate
    Patent number: 7771948
    Abstract: A newly identified hemoplasma agent, Candidatus Mycoplasma turicensis, is disclosed. Also disclosed are detection methods, screening methods and methods of diagnosis for the hemoplasma agent.
    Type: Grant
    Filed: April 30, 2008
    Date of Patent: August 10, 2010
    Assignee: The University of Zurich Veterinary Clinical Laboratory
    Inventors: Barbara Willi, Regina Hoffman-Lehmann, Hans Lutz, Felicitas Boretti
  • Compositions and methods for detecting
    Patent number: 7745595
    Abstract: Disclosed are oligonucleotides useful in methods for determining whether a sample contains Atopobium vaginae or has an increased likelihood of containing Atopobium vaginae, an organism which is seen in conjunction with bacterial vaginosis or is a causative agent of bacterial vaginosis. These oligonucleotides, which have nucleotide sequences derived from a segment of the genome of Atopobium vaginae, are useful as forward and reverse primers for a polymerase chain reaction using nucleic acids from a biological sample as a template, and as probes for detecting any resultant amplicon. Detection of an amplicon indicates the sample contains Atopobium vaginae or has an increased likelihood of containing Atopobium vaginae.
    Type: Grant
    Filed: August 10, 2006
    Date of Patent: June 29, 2010
    Assignee: Medical Diagnostic Laboratories, LLC
    Inventors: Jason Trama, Martin E. Adelson, Eli Mordechai
  • Nucleic acid probes and methods for detecting clinically important fungal pathogens
    Patent number: 7741461
    Abstract: The current invention relates to the field of detection and identification of clinically important fungi. More particularly, the present invention relates to species specific probes originating from the Internal Transcribed Spacer (ITS) region of rDNA for the detection of fungal species such as Candida albicans, Candida parapsilosis, Candida tropicalis, Candida kefyr, Candida krusei, Candida glabrata, Candida dubliniensis, Aspergillus flavus, Aspergillus versicolor, Aspergillus nidulans, Aspergillus fumigatus, Cryptococcus neoformans and Pneumocystis carinii in clinical samples, and methods using said probes.
    Type: Grant
    Filed: October 19, 2004
    Date of Patent: June 22, 2010
    Assignees: Innogenetics N.V., Enterprise Ireland, National University of Ireland Galway
    Inventors: Terry Smith, Majella Maher, Cara Martin, Geert Jannes, Rudi Rossau, Marjo Van der Weide
  • Genotyping assay to predict gamma glutamyl hydrolase (GGH) activity
    Patent number: 7741032
    Abstract: Single nucleotide polymorphisms (SNPs) in the gene encoding gamma glutamyl hydrolase (GGH) associated with reduced GGH activity are disclosed. The primary SNP is a change from a cytosine to a thymine at a position corresponding to nucleotide 511 of Genbank sequence accession no. NM 003878. Methods and kits for detecting these SNPs are provided, along with primers useful in detecting these SNP and for amplifying portions of the GGH gene containing these SNPs.
    Type: Grant
    Filed: July 8, 2004
    Date of Patent: June 22, 2010
    Assignee: St. Jude Children's Research Hospital, Inc.
    Inventors: William Edward Evans, Mary Relling, Qing Cheng
  • Detection and diagnosis of smoking related cancers
    Patent number: 7741034
    Abstract: Gene probes for specific regions of chromosome 3 (3p21.3) and chromosome 10 (10q22) have been found to be tools for the diagnosis and prognosis of smoking related cancers such as non-small cell lung cancer (NSCLC). For example, these probes can be used with fluorescence in situ hybridization (FISH), and used to stratify smokers into high and low risk groups, as well as determine a patients susceptibility to the development of smoking related cancers.
    Type: Grant
    Filed: September 28, 2004
    Date of Patent: June 22, 2010
    Assignee: Board of Regents, The University of Texas System
    Inventors: Ruth Katz, Feng Jiang
  • Feline hemoplasma isolate
    Patent number: 7741462
    Abstract: A newly identified hemoplasma agent, Candidatus Mycoplasma turicensis, is disclosed. Also disclosed are detection methods, screening methods and methods of diagnosis for the hemoplasma agent.
    Type: Grant
    Filed: May 3, 2006
    Date of Patent: June 22, 2010
    Assignee: The University of Zurich Veterinary Clinical Laboratory
    Inventors: Barbara Willi, Regina Hofmann-Lehmann, Hans Lutz, Felicitas S. Boretti
  • Methods and compositions for treating and diagnosing mood disorders, schizophrenia, and neuro-psychiatric disorders
    Patent number: 7736852
    Abstract: This invention provides: methods of determining a predisposition or susceptibility of a subject to a mood disorder, a schizophrenia, or a neuro-psychiatric disease or disorder, comprising detecting a presence of a polymorphism in a vesicular monoamine transporter 1 (VMAT1) gene or a haplotype comprising the polymorphism, and methods of treating a mood disorder, a schizophrenia, or a neuro-psychiatric disease or disorder in a subject, comprising contacting the subject with a composition that encodes a VMAT protein or modulates an expression or activity of same.
    Type: Grant
    Filed: December 12, 2005
    Date of Patent: June 15, 2010
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Wade Berrettini, Falk Lohoff
  • Markers for prenatal diagnosis and monitoring
    Patent number: 7718367
    Abstract: Methods and kits are provided for diagnosing, monitoring, or predicting preeclaimpsia in a pregnant woman, trisomy 18 and trisomy 21 in a fetus, as well as for detecting pregnancy in a woman, by quantitatively measuring in the maternal blood the amount of one or more RNA species derived from a set of genetic loci and comparing the amount of the RNA species with a standard control.
    Type: Grant
    Filed: March 17, 2006
    Date of Patent: May 18, 2010
    Assignee: The Chinese University of Hong Kong
    Inventors: Yuk-Ming Dennis Lo, Rossa Wai Kwun Chiu, Stephen Siu Chung Chim, Nancy Bo Yin Tsui
  • Mutations in the SLC40A1 gene associated to impaired iron homeostasis
    Patent number: 7718785
    Abstract: The present invention relates to mutations in the SLC40A1 gene coding for the ferroportin 1, associated to impaired iron homeostasis or to non-HFE hereditary hemochromatosis and to methods for the diagnosis of these hereditary diseases based on the identification of said mutations.
    Type: Grant
    Filed: June 9, 2004
    Date of Patent: May 18, 2010
    Inventor: Antonello Pietrangelo
  • Marker for prenatal diagnosis and monitoring
    Patent number: 7709194
    Abstract: The present invention relates to new methods for diagnosing a pregnancy-associated disorder by analyzing fetal DNA present in the mother's blood. More specifically, this invention relies on the discovery that the maspin gene is differentially methylated in fetal DNA and in maternal DNA and provides these new diagnostic methods, which distinguish fetal DNA from maternal DNA and detect prenatal disorders based on abnormalities in fetal DNA level and methylation status.
    Type: Grant
    Filed: June 3, 2005
    Date of Patent: May 4, 2010
    Assignee: The Chinese University of Hong Kong
    Inventors: Yuk Ming Dennis Lo, Rossa Wai Kwun Chiu, Stephen Siu Chung Chim, Yu-kwan Tong, Chunming Ding
  • Association of PDE4D allelic variants with stroke
    Patent number: 7709200
    Abstract: The present invention provides methods for detecting a predisposition for stroke in individuals by correlating allelic variants of the phosphodiesterase 4D (PDE4D) gene and hypertension status. The invention further contemplates kits and computer program products for detecting PDE4D polymorphisms indicative of a predisposition for stroke correlated with an individual's hypertension status.
    Type: Grant
    Filed: October 24, 2006
    Date of Patent: May 4, 2010
    Assignee: Roche Molecular Systems, Inc.
    Inventor: Victoria H. Brophy
  • Methods of detecting mutations associated with ataxia-ocular apraxia 2 (AOA2)
    Patent number: 7704691
    Abstract: Methods of identifying polymorphisms associated with ataxia-ocular apraxia 2 (AOA2), are described. The polymorphisms associated with AOA2 include specific mutations in the senataxin (SETX) gene. Also described are methods of diagnosis of AOA2, as well as methods of assessing an individual for carrier status for AOA2.
    Type: Grant
    Filed: January 22, 2007
    Date of Patent: April 27, 2010
    Assignee: Athena Diagnostics, Inc.
    Inventors: Corey D. Braastad, Narasimhan Nagan, Jeffrey G. Jones, William K. Seltzer, Susan Allen, Sat Dev Batish, Hui Zhu
  • Allelic form of the HMGA2 gene predisposing women to the formation of leiomyomas
    Patent number: 7700292
    Abstract: The present invention is directed to diagnostic assays that can be used to determine if a woman carries an allelic form of the HMGA2 gene that predisposes her to the formation of fibroid tumors. The invention also encompasses vectors containing this allele, cells transformed with these vectors and transgenic animals that carry at least one copy of the allele.
    Type: Grant
    Filed: November 14, 2006
    Date of Patent: April 20, 2010
    Assignee: The Bringham and Woman's Hospital, Inc.
    Inventors: Cynthia Morton, Jennelle Hodge, Karen Gross Huyck
  • Processes for isolating, amplifying and characterizing DNA
    Patent number: 7670768
    Abstract: Processes for isolating, amplifying, and characterizing DNA from biological materials are provided. DNA is isolated by contacting a biological material on a solid support which is preferably pre-treated with a lysing reagent. The isolation process is simple and efficient and provides a source of purified DNA without the use of harmful organic solvents such as urea and guanidine-based solvents. The purified DNA and remaining fractions of biological material may be characterized or amplified as necessary.
    Type: Grant
    Filed: February 2, 1999
    Date of Patent: March 2, 2010
    Assignee: Qiagen North American Holdings, Inc.
    Inventors: Ellen M. Heath, Ruth M. Shuman
  • Identification of the gene and mutation responsible for progressive rod-cone degeneration in dog and a method for testing same
    Patent number: 7671187
    Abstract: Tools and methods are provided for determining whether or not a dog is genetically normal, is a carrier of, or is affected with or predisposed to progressive rod-cone degeneration. The method is based on the detection of a transversion from G to A at position corresponding to nucleotide position 1298 of SEQ ID NO: 1.
    Type: Grant
    Filed: November 13, 2007
    Date of Patent: March 2, 2010
    Assignee: Cornell Research Foundation, Inc.
    Inventors: Gustavo Aguirre, Gregory M. Acland, Barbara Zangerl, Orly Goldstein, Susan Pearce-Kelling, Jeanette S. Felix, Duska J. Sidjanin
  • Methylation profile of breast cancer
    Patent number: 7666589
    Abstract: The present invention relates to compositions and methods for cancer diagnostics, including but not limited to, cancer markers. In particular, the present invention provides methods of identifying methylation patterns in genes associated with specific cancers.
    Type: Grant
    Filed: October 2, 2003
    Date of Patent: February 23, 2010
    Assignee: Northwestern University
    Inventors: Victor V. Levenson, Ronald B. Gartenhaus
  • Methylation altered DNA sequences as markers associated with human cancer
    Patent number: 7662549
    Abstract: There is disclosed 103 novel methylation-altered DNA sequences (“marker sequences”) that have distinct methylation patterns in cancer, compared to normal tissue. In many instances, these marker sequences represent novel sequences not found in the GenBank data base, and none of these marker sequences have previously been characterized with respect to their methylation pattern in human cancers including, but not limited to those of bladder and prostate. These 103 sequences have utility as diagnostic, prognostic and therapeutic markers in the treatment of human cancer, and as reagents in kits for detecting methylated CpG-containing nucleic acids.
    Type: Grant
    Filed: October 27, 2000
    Date of Patent: February 16, 2010
    Assignee: The University of Southern California
    Inventors: Isabel D. C. Markl, Peter A. Jones, Yoshitaka Tomigahara, Gangning Liang, Hualin Fu, Jonathan Cheng
  • Gene expression profiling of uterine serous papillary carcinomas and ovarian serous papillary tumors
    Patent number: 7659062
    Abstract: Oligonucleotide microarrays were used to profile and compare gene expression patterns between uterine serous papillary carcinoma and ovarian serous papillary carcinoma or normal endometrial epithelial cells. mRNA fingerprints readily distinguish the more biologically aggressive and chemotherapy resistant USPC from OSPC or NEC. Plasminogen activator inhibitor is the most highly up-regulated gene in OSPC relative to USPC, whereas the c-erbB2 gene product (HER-2/neu) is strikingly overexpressed in USPC relative to OSPC and may therefore represent a novel diagnostic and therapeutic marker for this highly aggressive subset of endometrial tumors.
    Type: Grant
    Filed: June 1, 2004
    Date of Patent: February 9, 2010
    Assignee: The Board of Trustee of the University of Arkansas System
    Inventor: Alessandro D. Santin